Soma Sengupta

Soma Sengupta (born 1968) is a British-American physician-scientist.

She is a specialty board certified neuro-oncologist board certified Neurologist, fellowship-trained in Integrative Medicine.

Her clinical interests span treatment of brain tumor patients, integrative approaches in neurology and oncology, as well as healthcare policy.

She is a full-time faculty member in the Departments of Neurology and Neurosurgery at the University of North Carolina at Chapel Hill, where she is a Full Professor, Vice Chair, and Chief of the Division of Neuro-Oncology.

She is also a Bye Fellow at Lucy Cavendish College, University of Cambridge, U.K.

Sengupta completed a PhD in Biochemistry (1994) and a MBBChir (2002), both at the University of Cambridge, U.K. She has a long-standing research interest in clinically important membrane transport proteins.

After her Ph.D. she worked in Professor Carolyn Slayman's laboratory at Yale University on membrane transport protein biology critical to cardiac function.

She was a Visiting Fellow at various institutions (2000-2007), which included immunology research on the TAP transporter at the Cambridge Institute of Medical Research with Wellcome Trust Principal Research Fellow Professor Paul Lehner, fungal membrane transport protein research with Professor Rajini Rao at Johns Hopkins, and pediatric brain tumor research with Professor Scott Pomeroy at Boston Children's Hospital, Boston.

She completed a Neurology Residency at Beth Israel Deaconess Medical Center-Harvard (2011), a Clinical Fellowship in Neuro-Oncology (2013) at Boston Children's Hospital/Dana-Farber Cancer Institute/Mass General, and an Integrative Medicine Fellowship (2023) at the Andrew Weil Center for Integrative Medicine, The University of Arizona.

Her first faculty appointment was as an Instructor in the Department of Neurology at Beth Israel Deaconess Medical Center, Boston.

She discovered that medulloblastoma tumor cell viability could be impaired by activating the GABA-A receptor with a new class of benzodiazepine analogs.

She then took an appointment in the Department of Neurology at Emory University, where in collaboration with biochemist Daniel Pomeranz Krummel (University of North Carolina at Chapel Hill) and medicinal chemist James Cook (University of Wisconsin-Milwaukee), reported on the regression of melanoma tumors in mice using benzodiazepine analogs by both a direct mechanism and by enhancing infiltration of immune cells into the tumor microenvironment.

She continued this line of research as the holder of the Harold C. Schott Endowed Chair of Molecular Therapeutics at the University of Cincinnati College of Medicine.

Currently, a major focus of her lab research explores how activating membrane transport proteins regulate cancer cell ion homeostastis and how they can be leveraged to induce apoptosis in disparate cancer cells, including primary and metastatic brain cancers.

She co-founded a corporation with Pomeranz Krummel and Cook to advance this strategy.

Her clinical research includes employing novel therapeutic apps to remediate neurological deficits in cancer patients caused by treatments.

She also is a clinical trialist centered in the neuro-oncology space.

She has authored/greater than 80 publications, a book on brain tumor patients that is aimed for patients and clinical trainees, two volumes of poetry, and two children's books.

She has featured on several news articles and TV interviews to discuss her research.

In 2021 Sengupta became a Fellow of the Royal College of Physicians.

She is also a Fellow of the AAN and ANA.

She has received many NIH training grants for her research including the R25, K12 and K08 as well as foundational support from the American Cancer Society, B*CURED, and the American Brain Tumor Association.

She has also been recognized for her clinical commitments, including recent receipt of the Leonard Tow Humanism in Medicine Award presented by The Arnold P. Gold Foundation (2023).

While training in the UK, she received funding from the Wellcome Trust and Medical Research Council.